Cullinan's Cash Falls To $313.8 Million — It Expects Funding To Last Into 2029

Taiho's lung-cancer combination application is now expected to be completed in November, rather than by year-end.

Share
Cullinan's Cash Falls To $313.8 Million — It Expects Funding To Last Into 2029

Cullinan Therapeutics, which is testing drugs for autoimmune diseases and cancer, reported Tuesday that its cash, investments and interest receivable fell to $313.8 million from $439.0 million at year-end. The company expects those resources to fund its current operating plan into 2029, according to its SEC filing and accompanying earnings release.

Spending And Losses Narrow

Cullinan's third-quarter loss narrowed to $49.4 million from $50.6 million a year earlier, or $0.74 per common share versus $0.77. Research spending declined to $40.2 million from $42.0 million, while administrative spending fell to $12.4 million from $13.6 million.

Interest income also declined, to $3.3 million from $5.1 million. For the first nine months, the loss totaled $152.8 million, compared with $169.2 million a year earlier; research spending was $126.7 million versus $144.5 million.

The company focuses on T cell engagers—drugs that direct the body's T cells toward target cells. Its programs include treatments for lupus, rheumatoid arthritis, Sjögren's disease and leukemia, alongside a lung-cancer collaboration with Taiho.

November Application, Approval-Linked Payments

Cullinan now expects Taiho to finish its FDA application for zipalertinib plus chemotherapy in November. When Taiho began the submission in October, completion was targeted for year-end.

The combination is being developed as an initial treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations. September's late-stage trial results showed a six-month benefit in median time before the cancer worsened compared with chemotherapy alone.

Cullinan is eligible for $100 million if the combination receives U.S. approval for first-line treatment, and $30 million upon second-line approval, plus half of U.S. profits. A separate application for zipalertinib alone in previously treated lung cancer remains under FDA review, with a target decision date of February 27, 2027.

December Data Across The Pipeline

Cullinan started a study in November pairing CLN-049 with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia. That early-to-mid-stage trial joins an October-started mid-stage study in relapsed or refractory leukemia that could support a registration application; the latter begins with dose optimization before expanding at the selected dose.

Updated CLN-049 dose-escalation findings in relapsed or refractory leukemia and myelodysplastic syndrome are scheduled for presentation at the American Society of Hematology meeting on December 13.

“This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications,” Cullinan President and CEO Nadim Ahmed said in the earnings release. The update will cover multiple-dose results from approximately 20 patients with lupus, rheumatoid arthritis and Sjögren's disease, longer follow-up for responding lupus and rheumatoid arthritis patients, and initial single-target-dose findings in Sjögren's disease.

Velinotamig, licensed from Chongqing Genrix Biopharmaceutical for autoimmune diseases outside Greater China, entered a global early-to-mid-stage study in October for immune thrombocytopenia and warm autoimmune hemolytic anemia. On Sunday, Cullinan announced preliminary findings from Genrix Bio's lupus study in China: eight of nine evaluable patients improved by at least four points on a disease-activity scale.

Among seven patients with elevated protein levels in their urine at baseline, five had rapid reductions and four achieved complete kidney responses. These remain preliminary trial findings, rather than approval or established treatment benefits.

The December clinical updates come before the FDA's February target decision on zipalertinib alone; Cullinan's approval-linked payments remain contingent on U.S. regulatory clearance.

Sources

More on Cullinan Therapeutics

All Cullinan Therapeutics (CGEM) coverage →